Hypermarcas (OTCMKTS:HYPMY - Get Free Report) saw a large growth in short interest during the month of July. As of July 31st, there was short interest totaling 900 shares, agrowthof800.0% from the July 15th total of 100 shares. Approximately0.0% of the company's stock are short sold. Based on an average daily volume of 287,800 shares, the short-interest ratio is currently 0.0 days. Based on an average daily volume of 287,800 shares, the short-interest ratio is currently 0.0 days. Approximately0.0% of the company's stock are short sold.
Analyst Ratings Changes
Separately, Scotiabank raised shares of Hypermarcas to a "strong-buy" rating in a research note on Thursday, July 17th.
Read Our Latest Research Report on HYPMY
Hypermarcas Price Performance
Shares of OTCMKTS HYPMY traded down $0.17 during midday trading on Thursday, reaching $4.04. The company's stock had a trading volume of 42,735 shares, compared to its average volume of 76,741. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.63. The company has a 50 day moving average price of $4.75 and a 200 day moving average price of $4.00. Hypermarcas has a one year low of $2.64 and a one year high of $5.92. The company has a market cap of $2.56 billion, a price-to-earnings ratio of 19.24 and a beta of 0.77.
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.12 EPS for the quarter. Hypermarcas had a net margin of 11.28% and a return on equity of 6.19%.
Hypermarcas Dividend Announcement
The company also recently disclosed a dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, July 1st will be paid a dividend of $0.0345 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a yield of 281.0%. Hypermarcas's dividend payout ratio (DPR) is presently 57.14%.
About Hypermarcas
(
Get Free Report)
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hypermarcas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hypermarcas wasn't on the list.
While Hypermarcas currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.